ViroGates

Västra Hamnen Corporate Finance Initiates Coverage of ViroGates

Del

ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test products, primarily for emergency departments in hospitals, today announces that Västra Hamnen Corporate Finance AB will initiate research coverage of ViroGates.

The research coverage is governed by an agreement made between ViroGates and Västra Hamnen Corporate Finance. The analysis comprises an independent review of the Company, its products, markets and competitors as well as a financial scenario that constitutes the basis of an estimated justified market capitalization of ViroGates.

In its initiation coverage report, Västra Hamnen Corporate Finance AB concludes:

“Our DCF model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50 given our current view of the risk and including only the Acute Care market in our model. We see potential for further valuation upgrades when the company has overcome certain risks and when it gets closer to addressing other market segments.”

The initiation coverage report is available at Västra Hamnen’s website and at ViroGates’ investor website click here

For additional information, please contact

CEO Jakob Knudsen
Tel. (+45) 2226 1355, Email:jk@virogates.com
ViroGates A/S - www.virogates.com

Certified Advisor

Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email:per.lonn@vhcorp.se

Information om ViroGates

ViroGates
ViroGates
Banevænget 13
3460 Birkerød

https://www.virogates.com/

ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics’ Cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. www.virogates.com

Følg pressemeddelelser fra ViroGates

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra ViroGates

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum